About the Cover
Inflammation is a known driver of some cancers, and cytokines involved in this tumor-promoting process are being investigated. However, the role of IL22, a cytokine present in patients' primary lung tumors and sera, has yet to be rigorously investigated. Khosravi et al. establish IL22 as an essential promoter of KRAS mutant lung cancer and identify the mechanism of tumor promotion by IL22. Comparison of mice with and without this cytokine showed that IL22's absence significantly reduced infiltration of tumor-supportive inflammatory cells into lung tumors and was detrimental to tumor proliferation, angiogenesis, and stemness. Thus, a lack of IL22 enhances antitumor responses and reduces tumor burden. Read more in this issue on page 788. Original immunofluorescence image from Fig. 5A. Artwork by Lewis Long.